COMMUNIQUÉS West-GlobeNewswire

TOMI Environmental Solutions Secures Three-Phase SteraMist iHP Order from Mexican Pharmaceutical Manufacturer Zeyco
29/10/2026
Multi-line Hybrid System deployment, sourced at INTERPHEX, extends TOMI's integrated automated SteraMist iHP decontamination platform into Latin American pharmaceutical manufacturing FREDERICK, Md., Oct. 29, 2026 (GLOBE [...]
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
29/10/2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. Virtue SAB’s [...]
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
29/10/2026
MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid [...]
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
29/10/2026
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 [...]
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
29/10/2026
ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Milestone Scientific Provides Major Commercial Growth Update as CompuFlo® Expands Across 30 Million+ Annual Global Epidural Procedures
29/10/2026
Company Reports 500+ U.S. Leads, Expanding Healthcare Network Relationships, Federal Market Access, International Distribution and 300+ Issued and Pending Patents Worldwide Just 2% Penetration of Estimated U.S. Epidural [...]
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
29/10/2026
Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ET ALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy [...]
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
29/10/2026
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Codexis to Report Third Quarter 2026 Financial Results on November 12
29/10/2026
REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it [...]
Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
29/10/2026
NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing [...]
Neocis Expands Yomi S® Clearance to Include Pterygoid Implant Placement
29/10/2026
Yomi S receives first and only U.S. FDA clearance for digital guided surgery for pterygoid implants MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Neocis ® , the global leader in robotic-assisted dental surgery announced that [...]
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
29/10/2026
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster [...]
Precision Neuroscience Expands Clinical Network Beyond the U.S. with First International Site in Abu Dhabi
29/10/2026
Working with clinical researchers at Cleveland Clinic Abu Dhabi, the brain-computer interface company takes next step toward bringing transformative neurotechnology to patients worldwide NEW YORK, Oct. 29, 2026 (GLOBE [...]
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
29/10/2026
Nonclinical studies demonstrated reductions in two key measures of neuropathic pain Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple cancer-related symptoms SOLANA [...]
University of St. Augustine for Health Sciences Welcomes Florida's Occupational Therapy Community to its New St. Augustine Campus for FOTA26
29/10/2026
Faculty talks on evidence-based practice and emerging approaches, student research, and USAHS’s Hacking for the Holidays toy build headline two days of learning in St. Augustine ST. AUGUSTINE, Fla., Oct. 29, 2026 (GLOBE [...]
Exagen Inc. to Participate in Upcoming Investor Conferences
29/10/2026
CARLSBAD, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in and meet with investors at the [...]
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
29/10/2026
NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
29/10/2026
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK ® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Clinical data for first combination of [...]
Tangram Announces First Participant Dosed in Phase 1 Trial of TGM-148, a Novel Investigational RNAi Medicine for Bleeding Disorders
29/10/2026
TGM-148 is designed to combine hemostatic efficacy with a favorable safety profile and low treatment burden Tangram’s second asset to enter the clinic in 2026 Phase 1 trial will evaluate TGM-148 in healthy volunteers, [...]

Pages